UA80718C2 - 2-thio-substituted imidazole derivatives and their use in pharmaceutics - Google Patents

2-thio-substituted imidazole derivatives and their use in pharmaceutics Download PDF

Info

Publication number: UA80718C2
Authority: UA; Ukraine
Prior art keywords: alkyl; halogen; rug; phenyl; substituted
Prior art date: 2002-08-20

Application number

UAA200502484A

Other languages

English (en)

Ukrainian (uk)

Inventor

Hans-Gunter Striegel

Volfgang Albrecht

Original Assignee

Merckle Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-20

Filing date

2003-08-20

Publication date

2007-10-25

2003-08-20 Application filed by Merckle Gmbh filed Critical Merckle Gmbh

2007-10-25 Publication of UA80718C2 publication Critical patent/UA80718C2/uk

Links

150000002460 imidazoles Chemical class 0.000 title claims abstract description 17
229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title abstract description 12
150000001875 compounds Chemical class 0.000 claims abstract description 125
102000004127 Cytokines Human genes 0.000 claims abstract description 12
108090000695 Cytokines Proteins 0.000 claims abstract description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
230000002519 immonomodulatory effect Effects 0.000 claims abstract description 6
210000000987 immune system Anatomy 0.000 claims abstract description 4
238000000034 method Methods 0.000 claims description 62
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
229910052736 halogen Inorganic materials 0.000 claims description 30
150000002367 halogens Chemical class 0.000 claims description 30
150000003254 radicals Chemical class 0.000 claims description 14
238000002360 preparation method Methods 0.000 claims description 12
125000001424 substituent group Chemical group 0.000 claims description 11
125000003118 aryl group Chemical group 0.000 claims description 10
229910052799 carbon Inorganic materials 0.000 claims description 8
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 5
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
230000003287 optical effect Effects 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
150000005840 aryl radicals Chemical class 0.000 claims description 3
125000002619 bicyclic group Chemical group 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
125000002947 alkylene group Chemical group 0.000 claims description 2
210000005056 cell body Anatomy 0.000 claims description 2
125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
125000000165 tricyclic carbocycle group Chemical group 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
230000009471 action Effects 0.000 abstract description 3
201000010099 disease Diseases 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
239000000243 solution Substances 0.000 description 70
238000006243 chemical reaction Methods 0.000 description 66
238000005160 1H NMR spectroscopy Methods 0.000 description 59
238000007429 general method Methods 0.000 description 57
-1 thiazolyl radical Chemical class 0.000 description 55
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 53
238000004440 column chromatography Methods 0.000 description 45
239000011541 reaction mixture Substances 0.000 description 38
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 37
239000000203 mixture Substances 0.000 description 37
238000005481 NMR spectroscopy Methods 0.000 description 31
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
230000015572 biosynthetic process Effects 0.000 description 28
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
238000000926 separation method Methods 0.000 description 26
238000003786 synthesis reaction Methods 0.000 description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
238000010992 reflux Methods 0.000 description 21
239000000725 suspension Substances 0.000 description 21
150000001412 amines Chemical class 0.000 description 20
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
239000002244 precipitate Substances 0.000 description 18
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
238000001816 cooling Methods 0.000 description 15
239000000284 extract Substances 0.000 description 15
NBGMRMDAEWWFIR-UHFFFAOYSA-N imidazole-2-thione Chemical class S=C1N=CC=N1 NBGMRMDAEWWFIR-UHFFFAOYSA-N 0.000 description 15
239000000706 filtrate Substances 0.000 description 13
239000000126 substance Substances 0.000 description 12
238000001665 trituration Methods 0.000 description 12
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 11
239000007864 aqueous solution Substances 0.000 description 11
238000000746 purification Methods 0.000 description 11
239000012047 saturated solution Substances 0.000 description 11
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
239000007787 solid Substances 0.000 description 10
239000012043 crude product Substances 0.000 description 9
229920006395 saturated elastomer Polymers 0.000 description 9
229960000583 acetic acid Drugs 0.000 description 8
239000008346 aqueous phase Substances 0.000 description 8
238000000354 decomposition reaction Methods 0.000 description 8
239000012362 glacial acetic acid Substances 0.000 description 8
239000012074 organic phase Substances 0.000 description 8
239000002253 acid Substances 0.000 description 7
150000001408 amides Chemical class 0.000 description 7
238000010438 heat treatment Methods 0.000 description 7
239000003921 oil Substances 0.000 description 7
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
238000004809 thin layer chromatography Methods 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000003110 anti-inflammatory effect Effects 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 6
229940116357 potassium thiocyanate Drugs 0.000 description 6
238000001953 recrystallisation Methods 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
SWLMSOXBPVFLNF-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-pyridin-4-ylethanone Chemical compound C1=CC(F)=CC=C1CC(=O)C1=CC=NC=C1 SWLMSOXBPVFLNF-UHFFFAOYSA-N 0.000 description 5
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 5
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
125000000217 alkyl group Chemical group 0.000 description 5
235000011114 ammonium hydroxide Nutrition 0.000 description 5
229910052786 argon Inorganic materials 0.000 description 5
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 5
230000003197 catalytic effect Effects 0.000 description 5
229930195733 hydrocarbon Natural products 0.000 description 5
125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 5
230000003993 interaction Effects 0.000 description 5
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 5
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
229910052717 sulfur Inorganic materials 0.000 description 5
238000012360 testing method Methods 0.000 description 5
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 4
PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 4
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
230000001476 alcoholic effect Effects 0.000 description 4
238000009835 boiling Methods 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
239000007789 gas Substances 0.000 description 4
150000002430 hydrocarbons Chemical class 0.000 description 4
150000002576 ketones Chemical class 0.000 description 4
125000001624 naphthyl group Chemical group 0.000 description 4
150000002923 oximes Chemical class 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
VWVZFHRDLPHBEG-UHFFFAOYSA-N 1-(chloromethyl)-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(CCl)C=C1 VWVZFHRDLPHBEG-UHFFFAOYSA-N 0.000 description 3
IRJGKBJLGZJJEL-UHFFFAOYSA-N 1-(chloromethyl)-4-methylsulfinylbenzene Chemical compound CS(=O)C1=CC=C(CCl)C=C1 IRJGKBJLGZJJEL-UHFFFAOYSA-N 0.000 description 3
DATDARDTUZHWMK-UHFFFAOYSA-N 2-hydroxy-5-methylsulfanylbenzoic acid Chemical compound CSC1=CC=C(O)C(C(O)=O)=C1 DATDARDTUZHWMK-UHFFFAOYSA-N 0.000 description 3
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 3
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
241001061127 Thione Species 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
235000013877 carbamide Nutrition 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
229910052593 corundum Inorganic materials 0.000 description 3
239000013078 crystal Substances 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
238000004821 distillation Methods 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
238000005984 hydrogenation reaction Methods 0.000 description 3
239000005457 ice water Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
125000004434 sulfur atom Chemical group 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
150000003672 ureas Chemical class 0.000 description 3
150000003673 urethanes Chemical class 0.000 description 3
229910001845 yogo sapphire Inorganic materials 0.000 description 3
UWHSPZZUAYSGTB-UHFFFAOYSA-N 1,1,3,3-tetraethylurea Chemical compound CCN(CC)C(=O)N(CC)CC UWHSPZZUAYSGTB-UHFFFAOYSA-N 0.000 description 2
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 2
LXPRVXKHIXWBJZ-UHFFFAOYSA-N 1-(chloromethyl)-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(CCl)C=C1 LXPRVXKHIXWBJZ-UHFFFAOYSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 2
YELDSRZWSMAJAM-UHFFFAOYSA-N 2-(2-chloropyridin-4-yl)-1-(4-fluorophenyl)ethanone Chemical compound C1=CC(F)=CC=C1C(=O)CC1=CC=NC(Cl)=C1 YELDSRZWSMAJAM-UHFFFAOYSA-N 0.000 description 2
FFZMECXFDGAEHI-UHFFFAOYSA-N 2-(hydroxymethyl)-4-methylsulfanylphenol Chemical compound CSC1=CC=C(O)C(CO)=C1 FFZMECXFDGAEHI-UHFFFAOYSA-N 0.000 description 2
VRSJMAPIRMHLTI-UHFFFAOYSA-N 2-amino-1-(4-fluorophenyl)-2-(2-methoxypyridin-4-yl)ethanone;hydrochloride Chemical compound Cl.C1=NC(OC)=CC(C(N)C(=O)C=2C=CC(F)=CC=2)=C1 VRSJMAPIRMHLTI-UHFFFAOYSA-N 0.000 description 2
PEAJNZNKOKIMPP-UHFFFAOYSA-N 2-amino-1-(4-fluorophenyl)-2-(2-propan-2-yloxypyridin-4-yl)ethanone;hydrochloride Chemical compound Cl.C1=NC(OC(C)C)=CC(C(N)C(=O)C=2C=CC(F)=CC=2)=C1 PEAJNZNKOKIMPP-UHFFFAOYSA-N 0.000 description 2
XJFYCHHZMXLQGS-UHFFFAOYSA-N 2-amino-2-(2-bromopyridin-4-yl)-1-(4-fluorophenyl)ethanone;hydrochloride Chemical compound Cl.C=1C=NC(Br)=CC=1C(N)C(=O)C1=CC=C(F)C=C1 XJFYCHHZMXLQGS-UHFFFAOYSA-N 0.000 description 2
MZVSTDHRRYQFGI-UHFFFAOYSA-N 2-chloro-4-methylpyridine Chemical compound CC1=CC=NC(Cl)=C1 MZVSTDHRRYQFGI-UHFFFAOYSA-N 0.000 description 2
MNNZINNZIQVULG-UHFFFAOYSA-N 2-chloroethylbenzene Chemical compound ClCCC1=CC=CC=C1 MNNZINNZIQVULG-UHFFFAOYSA-N 0.000 description 2
UEFUHPOUXWUJPA-UHFFFAOYSA-N 2-hydroxy-5-methylsulfanylbenzaldehyde Chemical compound CSC1=CC=C(O)C(C=O)=C1 UEFUHPOUXWUJPA-UHFFFAOYSA-N 0.000 description 2
QTCQXOXUIPNFNH-UHFFFAOYSA-N 2-hydroxy-5-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1O QTCQXOXUIPNFNH-UHFFFAOYSA-N 0.000 description 2
OKVJCVWFVRATSG-UHFFFAOYSA-N 3-hydroxybenzyl alcohol Chemical compound OCC1=CC=CC(O)=C1 OKVJCVWFVRATSG-UHFFFAOYSA-N 0.000 description 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
OUGKBBLPRJESSG-UHFFFAOYSA-N 4-(2-chloropyridin-4-yl)-5-(4-fluorophenyl)-1,3-dihydroimidazole-2-thione Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=C(Cl)N=CC=2)NC(=S)N1 OUGKBBLPRJESSG-UHFFFAOYSA-N 0.000 description 2
YKDXVAJHIMABPJ-UHFFFAOYSA-N 4-(3-chloropropyl)benzenesulfonyl chloride Chemical compound ClCCCC1=CC=C(S(Cl)(=O)=O)C=C1 YKDXVAJHIMABPJ-UHFFFAOYSA-N 0.000 description 2
JCJRWCIKESVJNQ-UHFFFAOYSA-N 4-(hydroxymethyl)-2-methylsulfanylphenol Chemical compound CSC1=CC(CO)=CC=C1O JCJRWCIKESVJNQ-UHFFFAOYSA-N 0.000 description 2
CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 2
IKLIRIKNLSNYOF-UHFFFAOYSA-N 4-methoxy-3-methylsulfanylbenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1SC IKLIRIKNLSNYOF-UHFFFAOYSA-N 0.000 description 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
MUXAWPOBIFIKIA-UHFFFAOYSA-N 5-chloro-2-hydroxy-3-methylsulfanylbenzoic acid Chemical compound CSC1=CC(Cl)=CC(C(O)=O)=C1O MUXAWPOBIFIKIA-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
FKRODWKYQVHZGS-UHFFFAOYSA-N N-[2-(4-fluorophenyl)-1-pyridin-4-ylethylidene]hydroxylamine Chemical compound C=1C=NC=CC=1C(=NO)CC1=CC=C(F)C=C1 FKRODWKYQVHZGS-UHFFFAOYSA-N 0.000 description 2
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
150000008041 alkali metal carbonates Chemical class 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
239000002585 base Substances 0.000 description 2
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000012259 ether extract Substances 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
238000000227 grinding Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229910052500 inorganic mineral Chemical class 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000007788 liquid Substances 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
FGTMHTRAJKTVQJ-UHFFFAOYSA-N methyl 5-chloro-3-chlorosulfonyl-2-hydroxybenzoate Chemical compound COC(=O)C1=CC(Cl)=CC(S(Cl)(=O)=O)=C1O FGTMHTRAJKTVQJ-UHFFFAOYSA-N 0.000 description 2
JCUQSWVHGVRETC-UHFFFAOYSA-N methyl 5-chlorosulfonyl-2-hydroxybenzoate Chemical compound COC(=O)C1=CC(S(Cl)(=O)=O)=CC=C1O JCUQSWVHGVRETC-UHFFFAOYSA-N 0.000 description 2
125000006431 methyl cyclopropyl group Chemical group 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
239000011707 mineral Chemical class 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000012452 mother liquor Substances 0.000 description 2
AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 2
SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 2
125000002971 oxazolyl group Chemical group 0.000 description 2
239000012071 phase Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000010926 purge Methods 0.000 description 2
HGHPGHVNTQSTNM-UHFFFAOYSA-N quinolin-2-ylmethanamine Chemical compound C1=CC=CC2=NC(CN)=CC=C21 HGHPGHVNTQSTNM-UHFFFAOYSA-N 0.000 description 2
CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
IXHNFOOSLAWRBQ-UHFFFAOYSA-N (3,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C(Cl)=C1 IXHNFOOSLAWRBQ-UHFFFAOYSA-N 0.000 description 1
RGXUCUWVGKLACF-UHFFFAOYSA-N (3-methylphenyl)methanamine Chemical compound CC1=CC=CC(CN)=C1 RGXUCUWVGKLACF-UHFFFAOYSA-N 0.000 description 1
YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
HMTSWYPNXFHGEP-UHFFFAOYSA-N (4-methylphenyl)methanamine Chemical compound CC1=CC=C(CN)C=C1 HMTSWYPNXFHGEP-UHFFFAOYSA-N 0.000 description 1
MTXQKSQYMREAGJ-UHFFFAOYSA-N (4-methylsulfanylphenyl)methanol Chemical compound CSC1=CC=C(CO)C=C1 MTXQKSQYMREAGJ-UHFFFAOYSA-N 0.000 description 1
PGOOBECODWQEAB-UHFFFAOYSA-N (E)-clothianidin Chemical compound [O-][N+](=O)\N=C(/NC)NCC1=CN=C(Cl)S1 PGOOBECODWQEAB-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
OXFSTTJBVAAALW-UHFFFAOYSA-N 1,3-dihydroimidazole-2-thione Chemical compound SC1=NC=CN1 OXFSTTJBVAAALW-UHFFFAOYSA-N 0.000 description 1
XTGVRZKBSFJWPZ-UHFFFAOYSA-N 1,3-dioxourea Chemical class O=NC(=O)N=O XTGVRZKBSFJWPZ-UHFFFAOYSA-N 0.000 description 1
JAKXLOFPUFLDDK-UHFFFAOYSA-N 1-(chloromethyl)-2-methylsulfanylbenzene Chemical compound CSC1=CC=CC=C1CCl JAKXLOFPUFLDDK-UHFFFAOYSA-N 0.000 description 1
DLYIAMKMDQBQQT-UHFFFAOYSA-N 1-(chloromethyl)-2-methylsulfinylbenzene Chemical compound CS(=O)C1=CC=CC=C1CCl DLYIAMKMDQBQQT-UHFFFAOYSA-N 0.000 description 1
MCTIRDUNZYSAKO-UHFFFAOYSA-N 1-(chloromethyl)-2h-naphthalen-1-ol Chemical compound C1=CC=C2C(O)(CCl)CC=CC2=C1 MCTIRDUNZYSAKO-UHFFFAOYSA-N 0.000 description 1
PGWSZBIOZFAJQR-UHFFFAOYSA-N 1-(chloromethyl)-3-methylsulfanylbenzene Chemical compound CSC1=CC=CC(CCl)=C1 PGWSZBIOZFAJQR-UHFFFAOYSA-N 0.000 description 1
ZYVYEJXMYBUCMN-UHFFFAOYSA-N 1-methoxy-2-methylpropane Chemical compound COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 1
125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
ZHKJHQBOAJQXQR-UHFFFAOYSA-N 1H-azirine Chemical compound N1C=C1 ZHKJHQBOAJQXQR-UHFFFAOYSA-N 0.000 description 1
XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 description 1
PROQHKXYFYOXPW-UHFFFAOYSA-N 2-(1H-imidazol-2-ylsulfanylmethyl)phenol Chemical class N1C(=NC=C1)SCC1=C(C=CC=C1)O PROQHKXYFYOXPW-UHFFFAOYSA-N 0.000 description 1
KWUNMXGYSDRFGV-UHFFFAOYSA-N 2-(4-fluorophenyl)-3-oxo-3-pyridin-4-ylpropanenitrile Chemical compound C1=CC(F)=CC=C1C(C#N)C(=O)C1=CC=NC=C1 KWUNMXGYSDRFGV-UHFFFAOYSA-N 0.000 description 1
MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
JHQBLYITVCBGTO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1 JHQBLYITVCBGTO-UHFFFAOYSA-N 0.000 description 1
LCFBWKCCSOYXOS-UHFFFAOYSA-N 2-amino-1-(4-fluorophenyl)-2-pyridin-4-ylethanone;hydrochloride Chemical compound Cl.C=1C=NC=CC=1C(N)C(=O)C1=CC=C(F)C=C1 LCFBWKCCSOYXOS-UHFFFAOYSA-N 0.000 description 1
XRZMKPGVXOSEQA-UHFFFAOYSA-N 2-amino-2-(2-chloropyridin-4-yl)-1-(4-fluorophenyl)ethanone;hydrochloride Chemical compound Cl.C=1C=NC(Cl)=CC=1C(N)C(=O)C1=CC=C(F)C=C1 XRZMKPGVXOSEQA-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
150000003930 2-aminopyridines Chemical class 0.000 description 1
DIABUJYZLNKYQJ-UHFFFAOYSA-N 2-azidopyridine Chemical class [N-]=[N+]=NC1=CC=CC=N1 DIABUJYZLNKYQJ-UHFFFAOYSA-N 0.000 description 1
LSZMVESSGLHDJE-UHFFFAOYSA-N 2-bromo-4-methylpyridine Chemical compound CC1=CC=NC(Br)=C1 LSZMVESSGLHDJE-UHFFFAOYSA-N 0.000 description 1
ZBFAXMKJADVOGH-UHFFFAOYSA-N 2-fluoro-4-methylpyridine Chemical compound CC1=CC=NC(F)=C1 ZBFAXMKJADVOGH-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
IFZZDINNCWFGEO-UHFFFAOYSA-N 2-propan-2-yloxypyridine Chemical class CC(C)OC1=CC=CC=N1 IFZZDINNCWFGEO-UHFFFAOYSA-N 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
ROPMXJGOXGHZNB-UHFFFAOYSA-N 3-(4-fluorophenyl)-5-pyridin-4-yl-1h-imidazole-2-thione Chemical compound C1=CC(F)=CC=C1N1C(=S)NC(C=2C=CN=CC=2)=C1 ROPMXJGOXGHZNB-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
XZBXAYCCBFTQHH-UHFFFAOYSA-N 3-chloropropylbenzene Chemical compound ClCCCC1=CC=CC=C1 XZBXAYCCBFTQHH-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
CPHGOBGXZQKCKI-UHFFFAOYSA-N 4,5-diphenyl-1h-imidazole Chemical class N1C=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CPHGOBGXZQKCKI-UHFFFAOYSA-N 0.000 description 1
ZTHOVRSZRGYAHB-UHFFFAOYSA-N 4-(4-bromophenyl)-5-pyridin-4-yl-1,3-dihydroimidazole-2-thione Chemical compound C1=CC(Br)=CC=C1C1=C(C=2C=CN=CC=2)NC(=S)N1 ZTHOVRSZRGYAHB-UHFFFAOYSA-N 0.000 description 1
FGTRKVMTLRECEA-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazole-2-thione Chemical compound C1=CC(Cl)=CC=C1C1=C(C=2C=CN=CC=2)NC(=S)N1 FGTRKVMTLRECEA-UHFFFAOYSA-N 0.000 description 1
FTJHIEVPYLNAKS-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(2-fluoropyridin-4-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=C(F)N=CC=2)NC(=S)N1 FTJHIEVPYLNAKS-UHFFFAOYSA-N 0.000 description 1
GYTYKWARQJEIBC-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(2-methoxypyridin-4-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1=NC(OC)=CC(C2=C(NC(=S)N2)C=2C=CC(F)=CC=2)=C1 GYTYKWARQJEIBC-UHFFFAOYSA-N 0.000 description 1
UVDNOPUFXVGRTP-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(2-propan-2-yloxypyridin-4-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1=NC(OC(C)C)=CC(C2=C(NC(=S)N2)C=2C=CC(F)=CC=2)=C1 UVDNOPUFXVGRTP-UHFFFAOYSA-N 0.000 description 1
QUSRTYDDDAFXMC-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazole-2-thione Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)NC(S)=N1 QUSRTYDDDAFXMC-UHFFFAOYSA-N 0.000 description 1
BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 1
RFZWUDLNHIWPJP-UHFFFAOYSA-N 4-hydroxy-3-methylsulfanylbenzoic acid Chemical compound CSC1=CC(C(O)=O)=CC=C1O RFZWUDLNHIWPJP-UHFFFAOYSA-N 0.000 description 1
BTJIUGUIPKRLHP-UHFFFAOYSA-M 4-nitrophenolate Chemical compound [O-]C1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-M 0.000 description 1
VZPSMMMKGUCJJQ-UHFFFAOYSA-N 4-phenyl-5-pyridin-4-yl-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC(C=2C=CC=CC=2)=C1C1=CC=NC=C1 VZPSMMMKGUCJJQ-UHFFFAOYSA-N 0.000 description 1
125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
241000038027 Amphisbaena Species 0.000 description 1
101100492689 Arabidopsis thaliana ATE2 gene Proteins 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
244000056139 Brassica cretica Species 0.000 description 1
235000003351 Brassica cretica Nutrition 0.000 description 1
235000003343 Brassica rupestris Nutrition 0.000 description 1
229910004709 CaSi Inorganic materials 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
101710112752 Cytotoxin Proteins 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
101000616562 Danio rerio Sonic hedgehog protein A Proteins 0.000 description 1
241000632511 Daviesia arborea Species 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
FHUODBDRWMIBQP-UHFFFAOYSA-N Ethyl p-anisate Chemical compound CCOC(=O)C1=CC=C(OC)C=C1 FHUODBDRWMIBQP-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
102000004961 Furin Human genes 0.000 description 1
108090001126 Furin Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000282838 Lama Species 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
150000007945 N-acyl ureas Chemical class 0.000 description 1
KKCBUQHMOMHUOY-UHFFFAOYSA-N Na2O Inorganic materials [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
241001318330 Nenia Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241001415849 Strigiformes Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
241001377938 Yara Species 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000003927 aminopyridines Chemical class 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229960003116 amyl nitrite Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000000326 anti-hypercholesterolaemic effect Effects 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
150000001502 aryl halides Chemical class 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
238000005102 attenuated total reflection Methods 0.000 description 1
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
238000005447 aza-Wittig reaction Methods 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
MKORBUHNKXGCSY-UHFFFAOYSA-N butylbenzene Chemical compound [CH2+]CCCC1=CC=CC=C1 MKORBUHNKXGCSY-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
OMEGHMBBBTYRFT-UHFFFAOYSA-N chloromethylcyclohexane Chemical compound ClCC1CCCCC1 OMEGHMBBBTYRFT-UHFFFAOYSA-N 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
CXQRNYIKPJXYLU-UHFFFAOYSA-N cis-pinidine Natural products CC=CC1CCCC(C)N1 CXQRNYIKPJXYLU-UHFFFAOYSA-N 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
MCRPKBUFXAKDKI-UHFFFAOYSA-N ethyl pyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=C1 MCRPKBUFXAKDKI-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000010855 food raising agent Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
125000005059 halophenyl group Chemical group 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000011068 loading method Methods 0.000 description 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
235000010460 mustard Nutrition 0.000 description 1
HWWVAHCWJLGKLW-UHFFFAOYSA-N n,n-dimethylhydroxylamine;hydron;chloride Chemical compound Cl.CN(C)O HWWVAHCWJLGKLW-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000002826 nitrites Chemical class 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
230000010494 opalescence Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
125000004660 phenylalkylthio group Chemical group 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
CXQRNYIKPJXYLU-ZHBVTVBMSA-N pinidine Chemical compound C\C=C\[C@H]1CCC[C@@H](C)N1 CXQRNYIKPJXYLU-ZHBVTVBMSA-N 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
239000000779 smoke Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
229950001870 spizofurone Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
BBDNZMUIQBRBJH-UHFFFAOYSA-N sulfurochloridic acid;toluene Chemical compound OS(Cl)(=O)=O.CC1=CC=CC=C1 BBDNZMUIQBRBJH-UHFFFAOYSA-N 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000000844 transformation Methods 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
206010047470 viral myocarditis Diseases 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Virology (AREA)
Obesity (AREA)
Oncology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Hematology (AREA)

UAA200502484A 2002-08-20 2003-08-20 2-thio-substituted imidazole derivatives and their use in pharmaceutics UA80718C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10238045A DE10238045A1 (de)	2002-08-20	2002-08-20	2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
PCT/EP2003/009219 WO2004018458A1 (de)	2002-08-20	2003-08-20	2-thio-substituierte imidazolderivate und ihre verwendung in der pharmazie

Publications (1)

Publication Number	Publication Date
UA80718C2 true UA80718C2 (en)	2007-10-25

Family

ID=31197117

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200502484A UA80718C2 (en)	2002-08-20	2003-08-20	2-thio-substituted imidazole derivatives and their use in pharmaceutics

Country Status (19)

Country	Link
US (1)	US7582660B2 (pl)
EP (1)	EP1539741A1 (pl)
JP (1)	JP2005539035A (pl)
KR (1)	KR20050058419A (pl)
CN (1)	CN100396677C (pl)
AU (1)	AU2003267000B2 (pl)
BR (1)	BR0313277A (pl)
CA (1)	CA2501849A1 (pl)
DE (1)	DE10238045A1 (pl)
HR (1)	HRP20050239A2 (pl)
IS (1)	IS7740A (pl)
MX (1)	MXPA05001985A (pl)
NO (1)	NO20051477L (pl)
PL (1)	PL375793A1 (pl)
RS (1)	RS20050131A (pl)
RU (1)	RU2331638C2 (pl)
UA (1)	UA80718C2 (pl)
WO (1)	WO2004018458A1 (pl)
ZA (1)	ZA200501455B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2007135955A (ru) *	2005-02-28	2009-04-10	Меркле Гмбх (De)	2-сульфинил-и 2-сульфонилзамещенные производные имидазола и их применение в качестве ингибиторов цитокина
EP1894925A1 (en) *	2006-08-24	2008-03-05	Merckle Gmbh	Imidazole compounds having an antiinflammatory effect
US8143294B2 (en)	2007-12-31	2012-03-27	Michael Burnet	2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors
JP5912946B2 (ja) *	2012-01-11	2016-04-27	株式会社Adeka	感光性樹脂組成物
WO2022067063A1 (en) *	2020-09-25	2022-03-31	Dana-Farber Cancer Institute, Inc.	Mutant selective egfr inhibitors and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4190666A (en) *	1975-08-11	1980-02-26	E. I. Du Pont De Nemours And Company	Anti-inflammatory 4,5-diarly-2-(substituted-thio)imidazoles and their corresponding sulfoxides and sulfones
DE2963572D1 (en) *	1978-04-11	1982-10-21	Ciba Geigy Ag	Mercapto-imidazole derivatives, their preparation, mercapto-imidazole derivatives for the treatment of inflammatory diseases and their pharmaceutical compositions
DE2823197A1 (de)	1978-05-24	1979-11-29	Schering Ag	Neue imidazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3025484A1 (de) *	1980-07-03	1982-02-04	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue imidazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3141063A1 (de) *	1981-10-13	1983-04-28	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue imidazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3504678A1 (de)	1985-02-12	1986-08-14	A. Nattermann & Cie GmbH, 5000 Köln	Neue imidazolyl-oxyalkansaeuren und -thioalkansaeuren, ihre derivate und verfahren zu ihrer herstellung
US4686231A (en)	1985-12-12	1987-08-11	Smithkline Beckman Corporation	Inhibition of 5-lipoxygenase products
SU1415725A1 (ru)	1986-11-17	1996-10-10	В.М. Виноградов	Дигидрохлорид 4-(4'-метоксифенил)-2-морфолиноэтилтио-5-фенилимидазола, повышающий физическую выносливость
JPS6440467A (en)	1987-08-04	1989-02-10	Hisamitsu Pharmaceutical Co	Novel substituted diphenylimidazole derivative
CA2003283A1 (en)	1988-12-05	1990-06-05	C. Anne Higley	Imidazoles for the treatment of atherosclerosis
MX9203711A (es)	1990-01-12	1992-07-01	Rhone Poulenc Rorer Sa	Derivados de imidazol y composiciones farmaceuticas que los contienen.
GB9005966D0 (en)	1990-03-16	1990-05-09	May & Baker Ltd	New compositions of matter
IL104369A0 (en)	1992-01-13	1993-05-13	Smithkline Beecham Corp	Novel compounds and compositions
US5364875A (en) *	1992-05-11	1994-11-15	The Du Pont Merck Pharmaceutical Company	Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5620999A (en)	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
AU8757098A (en) *	1997-06-30	1999-02-10	Ortho-Mcneil Pharmaceutical, Inc.	2-substituted imidazoles useful in the treatment of inflammatory diseases
DE19842833B4 (de) *	1998-09-18	2005-04-14	Merckle Gmbh	2-Arylalkylthio-imidazole, 2-Arylalkenylthio-imidazole und 2-Arylalkinylthio-imidazole als Entzündungs-Hemmstoffe und Hemmstoffe der Cytokin-Freisetzung
DE10107683A1 (de) *	2001-02-19	2002-08-29	Merckle Gmbh Chem Pharm Fabrik	2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
DE10114775A1 (de)	2001-03-26	2002-10-10	Gerhard Dannhardt	2-Mercapto-4,5-diarylimidazolderivate und ihre Verwendung in der Pharmazie
DE10222103A1 (de)	2002-05-17	2003-11-27	Merckle Gmbh Chem Pharm Fabrik	2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie

2002
- 2002-08-20 DE DE10238045A patent/DE10238045A1/de not_active Withdrawn
2003
- 2003-08-20 HR HR20050239A patent/HRP20050239A2/hr not_active Application Discontinuation
- 2003-08-20 CN CNB038197502A patent/CN100396677C/zh not_active Expired - Fee Related
- 2003-08-20 CA CA002501849A patent/CA2501849A1/en not_active Abandoned
- 2003-08-20 PL PL03375793A patent/PL375793A1/pl not_active Application Discontinuation
- 2003-08-20 RU RU2005107726/04A patent/RU2331638C2/ru not_active IP Right Cessation
- 2003-08-20 WO PCT/EP2003/009219 patent/WO2004018458A1/de not_active Ceased
- 2003-08-20 MX MXPA05001985A patent/MXPA05001985A/es active IP Right Grant
- 2003-08-20 KR KR1020057002947A patent/KR20050058419A/ko not_active Ceased
- 2003-08-20 US US10/524,486 patent/US7582660B2/en not_active Expired - Fee Related
- 2003-08-20 EP EP03747916A patent/EP1539741A1/de not_active Withdrawn
- 2003-08-20 UA UAA200502484A patent/UA80718C2/uk unknown
- 2003-08-20 JP JP2004530221A patent/JP2005539035A/ja active Pending
- 2003-08-20 RS YUP-2005/0131A patent/RS20050131A/sr unknown
- 2003-08-20 AU AU2003267000A patent/AU2003267000B2/en not_active Ceased
- 2003-08-20 BR BR0313277-3A patent/BR0313277A/pt not_active IP Right Cessation
2005
- 2005-02-18 ZA ZA200501455A patent/ZA200501455B/en unknown
- 2005-03-14 IS IS7740A patent/IS7740A/is unknown
- 2005-03-18 NO NO20051477A patent/NO20051477L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1675197A (zh)	2005-09-28
KR20050058419A (ko)	2005-06-16
MXPA05001985A (es)	2005-05-27
CA2501849A1 (en)	2004-03-04
AU2003267000A1 (en)	2004-03-11
NO20051477L (no)	2005-05-19
EP1539741A1 (de)	2005-06-15
DE10238045A1 (de)	2004-03-04
US7582660B2 (en)	2009-09-01
US20060235054A1 (en)	2006-10-19
HRP20050239A2 (en)	2005-10-31
RU2331638C2 (ru)	2008-08-20
CN100396677C (zh)	2008-06-25
IS7740A (is)	2005-03-14
RS20050131A (sr)	2007-06-04
RU2005107726A (ru)	2006-01-20
BR0313277A (pt)	2005-06-21
WO2004018458A1 (de)	2004-03-04
JP2005539035A (ja)	2005-12-22
AU2003267000B2 (en)	2009-05-28
PL375793A1 (pl)	2005-12-12
ZA200501455B (en)	2006-10-25

Publication	Publication Date	Title
EP2336107B1 (en)	2015-09-23	Proton pump inhibitors
EP2467378B1 (en)	2016-07-27	Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
EP3480193B1 (en)	2024-05-29	Pyrazole derivatives as alk5 inhibitors and uses thereof
CZ9904750A3 (cs)	2001-12-12	Nové substituované imidazolové sloučeniny
JP2002509537A (ja)	2002-03-26	新規なシクロアルキル置換イミダゾール化合物
HU228172B1 (en)	2013-01-28	Pharmacologically active pyridine derivatives and their preparation
KR19990022574A (ko)	1999-03-25	이미다졸 화합물
KR19990077165A (ko)	1999-10-25	신규한 치환 이미다졸 화합물
CN106573001A (zh)	2017-04-19	作为蛋白激酶抑制剂的氨基哒嗪酮化合物
PT1042293E (pt)	2008-04-18	Compostos de piridazina e piridina substituídos e as suas utilizações farmacêuticas
EA031076B1 (ru)	2018-11-30	Ингибиторы протеинкиназы
JP2000503304A (ja)	2000-03-21	新規シクロアルキル置換イミダゾール
EP2155683A2 (en)	2010-02-24	Pyridone derivatives as p38a mapk inhibitors
JP2004516267A (ja)	2004-06-03	ヘテロアリール尿素神経ペプチドｙｙ５レセプターアンタゴニスト
TW200306834A (en)	2003-12-01	Aminopyrimidine compound and pharmaceutical use thereof
AU2002247726C1 (en)	2006-08-17	2-Thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry
JP2000505428A (ja)	2000-05-09	ヒスタミンｈ▲下３▼レセプターリガンド
HUP0401949A2 (hu)	2005-01-28	4-Imidazolin-2-on-származékok
TWI527808B (zh)	2016-04-01	乙炔基衍生物
TWI458710B (zh)	2014-11-01	乙炔基衍生物
EP3052484B1 (en)	2018-03-21	Sulfonylindole derivatives and method for preparing the same
RU2331638C2 (ru)	2008-08-20	2-тиозамещенные производные имидазола и их применение в фармацевтике
CA1257274A (en)	1989-07-11	Amidine derivatives of 2-substituted 4- phenylimidazole
NZ538222A (en)	2006-11-30	2-Thio-substituted imidazole derivatives and their use in pharmaceuticals
HK1063462A (en)	2004-12-31	4-imidazolin-2-one compounds